Evidence map›Paper›PMID 26287424›Full record

SynthesisMedicine2015

Association of Vitamin D Receptor Cdx-2 Polymorphism With Cancer Risk: A Meta-Analysis.

Zhi-Ming Dai, Yu-Lang Fei, Wang-Gang Zhang, Jie Liu, Xing-Mei Cao, Qiu-Min Qu, Yan-Chun Li, Shuai Lin, Meng Wang, Zhi-Jun Dai

Abstract readMeta-Analysis
In one paragraph

Synthesis in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhi-Ming DaiFrom the Department of Hematology (Z-MD, W-GZ, JL, X-MC); Department of Anesthesia (Z-MD), and Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China (SL, MW, Z-JD); Department of Neurology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China (Y-LF, Q-MQ); and Department of Hematological Genetics, Shaanxi Provincial People's Hospital, Xi'an, China (Y-CL).
Yu-Lang Fei
Wang-Gang Zhang
Jie Liu
Xing-Mei Cao
Qiu-Min Qu
Yan-Chun Li
Shuai Lin
Meng Wang
Zhi-Jun Dai

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D receptor (VDR) Cdx-2 polymorphism (rs11568820) has been indicated to be associated to cancer susceptibility. However, published studies reported mixed results. This meta-analysis was conducted to get a more accurate estimation of the association between Cdx-2 polymorphism and cancer risk.We identified 25 independent studies with a total of 34,018 subjects published prior to March 2015. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the susceptibility to cancer. Separate analyses were conducted on features of the population such as ethnicity, source of controls, and cancer types.Meta-analysis results showed that Cdx-2 polymorphism significantly increased cancer risk in the homozygous model in overall analysis. According to the further stratified analysis, significant association was found between Cdx-2 variant and cancer risk in American-Africans in the homozygous, recessive, and dominant comparison models. However, no significant associations were found in Caucasians and Asians. When stratified by different cancer types, significant association was observed between Cdx-2 variant and an increased risk of colorectal cancer in the homozygous, recessive, and dominant models. In addition, ovarian cancer susceptibility increased based on the homozygous and dominant comparison models.Our study indicated that VDR Cdx-2 polymorphism was associated with an increased cancer risk, particularly in American-Africans, colorectal, and ovarian cancers. However, other factors may impact on the association. Further multicenter studies are needed to confirm the effects of Cdx-2 polymorphism on cancer susceptibility.

Indexed as

EthnicityGenetic Predisposition to DiseaseHumansNeoplasmsPolymorphism, GeneticReceptors, CalcitriolReceptors, CalcitriolVDR protein, human

Identifiers

PMID26287424
PMCPMC4616440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.